RxDoctor Payments Data

Ven Chiang, MD

Nephrology · Valdosta, GANPI 1447367453

Payments from drug & device makers

$4,448in general payments, 2019–2025

Across 214 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$953
  • Bayer$701
  • Otsuka America Pharmaceutical, Inc.$622
  • Fresenius USA Marketing, Inc.$564
  • Travere Therapeutics, Inc.$330
  • OPKO Pharmaceuticals, LLC$248
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,37298%
  • Education$762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,448 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$208,810
Medicare patients
310
Services billed
1,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone182$152,727
VelphoroSucroferric Oxyhydroxide59$102,558
FarxigaDapagliflozin Propanediol136$100,400
VeltassaPatiromer Calcium Sorbitex29$34,867
JardianceEmpagliflozin13$19,484
LokelmaSodium Zirconium Cyclosilicate18$18,429
Sevelamer Carbonate129$13,343
Calcium Acetate134$12,404
EliquisApixaban13$8,460
ProsolParenteral Amino Acid 20% No.122$1,932
Chlorthalidone78$1,436
Calcitriol47$1,363
Valsartan75$1,178
Losartan Potassium135$1,069
Hydralazine Hcl73$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$701$152,727182 claims
AstraZenecaFarxiga, Lokelma$953$118,829154 claims
Fresenius USA Marketing, Inc.Velphoro$564$102,55859 claims
ANI Pharmaceuticals, Inc.Valsartan$101$1,17875 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.

Other nephrology in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →